Vaxxinity, Inc. (VAXX)

Market Cap	3.17M +66.7%
Revenue (ttm)	n/a
Net Income	-56.93M
EPS	-0.45
Shares Out	126.75M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	251
Open	0.0250
Previous Close	0.0001
Day's Range	0.0250 - 0.0250
52-Week Range	0.000001 - 0.2000
Beta	-71.73
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Vaxxinity

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer’s disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated α-synuclein in the brain to fight parkinson’s disease and other synucleinopathies, such as Lewy body dementia an...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2021
• Employees: 65
• Stock Exchange: OTCMKTS
• Ticker Symbol: VAXX

Financial Performance

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Nov 9, 2026

Data Sources Report a data error